Señales en vivo de TRIB | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 15:46):
Our systems believe the stock currently is undervalued by 0.09% compare to its pairs and should correct upwards.

Stats
Volumen de hoy	15 149
Volumen promedio	42 432
Capitalización de mercado	17.33M
EPS	$-0.720 ( Q4 \| 2024-04-30 )
Próxima fecha de ganancias	( $0 ) 2024-07-04
Last Dividend	$1.100 ( 2015-06-05 )
Next Dividend	$0 ( N/A )
P/E	0.500 (Sector) 42.63 (Industry) 0
ATR14	$0.0530 (2.49%)

ACRS 8.64%

AKU -17.87%

APDN 32.23%

BDSX -0.65%

BIOC 0.00%

BNGO -2.32%

BNR -2.86%

CDNA -1.19%

CEMI 0.22%

CHEK 3.54%

CNTG 2.76%

CSTL -3.17%

DMTK -11.32%

DRIO -0.84%

EXAS 0.41%

FLDM -7.02%

FLGT 2.60%

GENE -6.04%

GH -2.22%

GTH 0.12%

HTGM 0.00%

ICLR 1.16%

IDXX -1.99%

ILMN 1.26%

ISPC -1.88%

LAB -1.41%

LMDX 0.00%

MDXH -2.51%

ME -4.14%

MEDP -0.85%

MYGN -1.94%

MYNZ -16.20%

NDRA -3.81%

NEO 0.50%

NEOG -3.61%

NOTV -4.82%

NTRA -0.47%

OCDX 0.92%

OLK 0.18%

OPGN -0.39%

OPK -1.99%

PMD -2.89%

PRPO 0.89%

PSNL 1.70%

RDNT -0.56%

SERA 3.55%

SHC -2.74%

SQL 0.00%

STIM -4.17%

STRR -4.19%

STRRP -5.05%

SYNH 0.02%

TRIB 2.90%

TTOO 0.37%

TWST -0.42%

VIVO 0.00%

XGN 0.55%

Insider Trading

Date	Person	Action	Amount	type
2004-02-13	Robert R Mccormick Tribune Foundation	Sell	65 200	Common Stock
2004-02-17	Robert R Mccormick Tribune Foundation	Sell	92 000	Common Stock
2004-02-18	Robert R Mccormick Tribune Foundation	Sell	17 800	Common Stock

INSIDER POWER
0.00
Last 3 transactions
Buy: 0 \| Sell: 175 000

Correlación (AI algo v.1.1b): Undervalued: 0.09% $2.13 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Volumen Correlación

Largo: 0.21 (neutral)

Corto: 0.14 (neutral)

Signal:(56.195) Neutral

Trinity Biotech PLC Correlación

10 Correlaciones Más Positivas
FRST	0.852
TOI	0.851
EMKR	0.848
HA	0.843
MPAA	0.832
ADBE	0.83
DOMO	0.829
ENSC	0.828
AKAM	0.828
BSBK	0.825

10 Correlaciones Más Negativas
CTRE	-0.833
SSIC	-0.833
MMLP	-0.817
TNDM	-0.812
INCR	-0.811
BZFD	-0.81

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Trinity Biotech PLC Correlación - Moneda/Commodity

0.13
( neutral )

0.34
( neutral )

0.00
( neutral )

0.10
( neutral )

-0.19
( neutral )

Trinity Biotech PLC Finanzas

Annual	2023
Ingresos:	$56.83M
Beneficio Bruto:	$18.50M (32.56 %)
EPS:	$-3.14

FY	2023
Ingresos:	$56.83M
Beneficio Bruto:	$18.50M (32.56 %)
EPS:	$-3.14

FY	2022
Ingresos:	$74.78M
Beneficio Bruto:	$22.05M (29.48 %)
EPS:	$-6.08

FY	2021
Ingresos:	$92.97M
Beneficio Bruto:	$38.08M (40.96 %)
EPS:	$0.0400

Financial Reports:

No articles found.

Trinity Biotech PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Trinity Biotech PLC Dividend Information - No Dividend Player

Dividend Sustainability Score: 0.784 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$2.00	2011-06-07
Last Dividend	$1.100	2015-06-05
Next Dividend	$0	N/A
Payout Date	2015-07-01
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	$5.95	--
Avg. Dividend % Per Year	0.00%	--
Score	0.55	--
Div. Sustainability Score	0.784
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2025-03-31)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.55

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2011	$2.00	4.67%
2012	$0.750	1.49%
2013	$1.000	1.36%
2014	$1.100	0.88%
2015	$1.100	1.21%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
05 Jun 2015	$1.100	27 May 2015	09 Jun 2015	01 Jul 2015
06 Jun 2014	$1.100	23 May 2014	10 Jun 2014	01 Jul 2014
06 Jun 2013	$1.000	03 Jun 2013	10 Jun 2013	01 Jul 2013
06 Jun 2012	$0.750	05 Jun 2012	08 Jun 2012	22 Jun 2012
07 Jun 2011	$2.00	27 May 2011	09 Jun 2011	23 Jun 2011

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Diamond	2024-09-16	Monthly	14	15.03%	9.60
DMLP	Dividend Diamond	2024-04-26	Quarterly	22	10.71%	9.35
OXSQ	Dividend Diamond	2024-09-16	Monthly	21	12.73%	9.02
ARLP	Dividend Royal	2024-05-07	Quarterly	26	9.67%	8.87
PNNT	Dividend Royal	2024-06-14	Monthly	18	9.49%	8.82
MFIC	Dividend Royal	2024-06-11	Quarterly	21	10.89%	8.79
SPOK	Dividend Royal	2024-05-23	Quarterly	20	8.73%	8.72
PSEC	Dividend Royal	2024-06-25	Monthly	21	9.03%	8.65
SBLK	Dividend Royal	2024-06-06	Quarterly	17	13.10%	8.63
GBDC	Dividend Royal	2024-11-29	Bi-Monthly	15	8.53%	8.62

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.380	1.500	-7.59	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.238	1.200	-7.95	-9.54	[0 - 0.3]
returnOnEquityTTM	1.138	1.500	10.00	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.02	0.800	4.91	3.93	[1 - 3]
quickRatioTTM	1.025	0.800	8.68	6.94	[0.8 - 2.5]
cashRatioTTM	0.253	1.500	9.70	10.00	[0.2 - 2]
debtRatioTTM	0.834	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	-3.30	1.000	-2.33	-2.33	[3 - 30]
operatingCashFlowPerShareTTM	-1.676	2.00	-0.559	-1.117	[0 - 30]
freeCashFlowPerShareTTM	-2.07	2.00	-1.037	-2.07	[0 - 20]
debtEquityRatioTTM	-3.30	-1.500	-10.00	10.00	[0 - 2.5]
grossProfitMarginTTM	0.325	1.000	7.92	7.92	[0.2 - 0.8]
operatingProfitMarginTTM	-0.457	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.197	1.000	-2.21	-2.21	[0.2 - 2]
assetTurnoverTTM	0.628	0.800	9.15	7.32	[0.5 - 2]
Total Score				0.784

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.878	1.000	-0.190	0	[1 - 100]
returnOnEquityTTM	1.138	2.50	2.59	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-2.07	2.00	-0.692	-2.07	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.676	2.00	-0.559	-1.117	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0113	1.500	-3.26	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.262	1.000	-9.06	0	[0.1 - 0.5]
Total Score				-1.017

Trinity Biotech PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Trinity Biotech PLC

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Actualizaciones en tiempo real para Trinity Biotech PLC [TRIB]

Upcoming Earnings Alert